



PRESS RELEASE



Unilabs and Siemens Healthineers launch strategic partnership for latest diagnostic testing infrastructure to improve patients' care

Geneva and Erlangen – 2 February 2023 –: Unilabs, a leading diagnostic services provider, and Siemens Healthineers, a leading medical technology company, announced today a multi-year agreement valued at over €200 million. Unilabs has invested in Siemens Healthineers' top-notch technology and acquired more than 400 laboratory analysers to further improve its laboratory infrastructure to offer an unparalleled service to its customers.

"Delivering the best possible patient care is at the heart of everything we do, and we will continue to invest in the latest technology to further boost our services," said Michiel Boehmer, Unilabs' CEO. "Our CARE BIG mantra is driving us in our quest to build the most-digitally driven diagnostics group – enabling better decisions for a healthier tomorrow."

Under this agreement, Unilabs will continue modernising its healthcare infrastructure across its network to improve customer service and quality, and thereby improve patient health. The solutions Siemens Healthineers provides will enhance Unilabs' laboratory operations, throughput, and clinical equivalence across its testing network.

In the first years, Siemens Healthineers will install high- and mid-volume immunoassay and clinical chemistry analysers, including the Atellica Solution and Atellica CI 1900¹, sample handlers, haemostasis analysers, and automation solutions.

"Siemens Healthineers is uniquely positioned to add value through a portfolio of products that work in harmony to scale technology, especially as testing demand grows," said Sharon Bracken, Head of Diagnostics for Siemens Healthineers. "Our solutions help on many levels. They can improve cost savings and profitability through integrated reagents and consumables, deliver sophisticated intelligence software for better data analytics, and reduce unnecessary workflow friction with intuitive system user interfaces. We look forward to how our collaboration with Unilabs, along with its expanded investment in Siemens Healthineers technology, will benefit the company's laboratory operations and patient care for years to come."

Commitment to Sustainability

Unilabs will also partner with Siemens Healthineers to support combating climate change and save local resources. Both companies are deeply committed to sustainability.

"We are strongly committed to sustainability, and this partnership will also reduce our laboratories' environmental footprint by implementing Siemens Healthineers' proven technologies and methodologies," said Dr Christian Rebhan, Unilabs' President - Scientific Business Units and Chief Medical Officer.

¹ Not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.

Media contact:

Sandra Lastra, Group Communications, Unilabs

e: sandra.lastra@unilabs.com

Kimberly Nissen, PR Manager, Siemens Healthineers

e: Kimberly.Nissen@siemens-healthineers.com

About Unilabs

Unilabs is one of Europe's leading diagnostics companies, offering a complete range of laboratory, pathology, and imaging services to patients across four continents. A leading digital champion covering the full diagnostic spectrum, Unilabs' over 13,000 people improve lives every day.

Unilabs invests heavily in technology, equipment, and people – using digital technologies in its state-of-the-art laboratories and imaging institutes to improve the lives of close to 100 million people every year.

About Siemens Healthineers AG

(Listed in Frankfurt, Germany: SHL) Pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion. Further information is available at www.siemens-healthineers.com